İbrahim ÜNSAL, Canan UÇAR, Ergül TUNÇBİLEK, Sevim BALCI

Correlation Between Down Syndrome and the Level of Placental Alkaline Phosphatase in Amniotic Fluid

The aim of this study was to investigate the correlation between Down syndrome and the level of placental alkaline phosphatase (PLAP) in amniotic fluid. A total of 279 amniotic fluid samples taken between 14 and 24 gestational weeks were investigated in this study. Karyotype analysis was made in all samples. In 10 samples trisomy 21 was determined, in one sample trisomy 18, in two samples 47,XXY, in six samples various structural chromosomal anomalies and in 260 samples normal karyotype. PLAP was measured using a fluorometric heat inactivation assay. Mean PLAP multiples of normal gestational median (MOM) value in samples with Down syndrome was 0.44 MOM, and in those with normal karyotype was 1.14 MOM. In fetuses with Down syndrome, amniotic fluid PLAP levels were significantly reduced (p = 0.002). There was no difference between mean PLAP MOM values in samples with normal karyotype and in those with structural chromosomal abnormality (p = 0.47). When 0.37 MOM was accepted as a cut-off value of PLAP activity in amniotic fluid, detection rate (sensitivity) of the test was 50%, specificity was 94%, and false-positive rate was 5.8%. We conclude that PLAP levels are reduced in the amniotic fluid of women carrying a fetus with Down syndrome.

Anahtar Kelimeler:

PLAP (placental alkaline phosphatase), Down syndrome, amniotic fluid

Correlation Between Down Syndrome and the Level of Placental Alkaline Phosphatase in Amniotic Fluid

Keywords:

PLAP (placental alkaline phosphatase), Down syndrome, amniotic fluid,

PDF

___

Accardo PJ, Capute AJ. Mental retardation. Principles and Practice of Pediatrics (2nd ed) (Eds. Oski FA, DeAngelis CD, Feigin RD, McMillan JA, Warshaw JB) (Vol.1) JB Lippincott Co. Philadelphia, 643-679, 1994.
Tunnessen WW. Common syndromes with morphologic abnormalities. Principles and Practice of Pediatrics (2nded) (Eds. Oski FA, DeAngelis CD, Feigin RD, McMillan JA, Warshaw JB) (Vol.1) JB Lippincott Co. Philadelphia, 2176-2200, 1994.
Wald NJ, Cuckle HS, Densem JM et al. Maternal screening for Down syndrome in early pregnancy. Br J Med 297: 883-887, 1988. 4. Haddow JE, Palomaki GE, Knight GJ et al. Prenatal screening for Down’s syndrome with use of maternal serum markers. N Engl J Med 32: 588-593, 1992.
Stene J, Mikkelsen M. Down syndrome and other chromosome disorders. Antenatal and Neonatal Screening (Ed. Wald NJ) Oxford University Press. Oxford, 74-105, 1984.
Youing S, Gregson N, Jacobs P. The efficacy of maternal age screening for Down’s syndrome in Wessex. Prenat Diagn 14: 419-425, 1991.
Hook EB, Schreinemachers DM, Cross PK. Use of prenatal
cytogenetic diagnosis in New York State. N Engl J Med 305: 1410-1413, 1981.
Brocklehurst D, Wilde CE. Amniotic fluid alkaline phosphatase, gama-glutamyl transferase, and alkaline phosphatase as an index of fetal lung maturity. Clin Chem 26: 588-591, 1980.
Dictus-Vermeulen C, Ameryckx J, Gueuning C et al. Alkaline phosphatase isoenzyme pattern in human amniotic fluid is dependent on the level of total activity. Implications in cystic fibrosis diagnosis. Clin Chim Acta 173: 173-182, 1988.
Aitken DA, Syvertsen BS, Crossley JA et al. Heat-stable and immunoreactive placental alkaline phosphatase in maternal serum from Down’s syndrome and trisomy 18 pregnancies. Prenat Diagn 16: 1051-1054, 1996.
Vergnes H, Grozdea J, Denier C et al. Lower alkaline phosphatase activity and occurrence of an abnormal hybrid intestinal/tissue non-specific isoform in Down syndrome amniotic fluids. Early Hum Dev 58: 17-24, 2000.
Cuckle HS, Wald NJ. Principles of screening. Antenatal and Neonatal Screening. (Ed. Wald NJ) Oxford University Press. Oxford, 1-22, 1984.
Ind TE, Iles RK, Wathen NC et al. Low level of amniotic fluid placental alkaline phosphatase in Down’s syndrome. Br J Obstet Gynaecol 100: 847-849, 1993.
Ind TE, Iles RK, Wathen NC et al. Second trimester amniotic fluid placental alkaline phosphatase levels are low in Down’s syndrome but not in other fetal abnormalities. Early Hum Dev 37: 39-44, 1994.
Cuckle HS, Wald NJ, Lindenbaum RH. Maternal serum alpha- fetoprotein measurement: a screening test for Down syndrome. Lancet 1: 926-929, 1984.
Canick JA, Knight GJ, Palomaki GE et al. Low second-trimester maternal serum unconjugated oestriol in pregnancies with Down’s syndrome. Br J Obstet Gynaecol 95: 330-333, 1988.
Wald NJ, Cuckle HS. Biochemical screening. Prenatal Diagnosis and Screening. (Eds. Brock DJH, Rodeck CH, Ferguson-Smith MA) Churchill Livingstone. Philadelphia, 563-577, 1992.
Brock DJH, Barron L, Holloway S et al. First-trimester maternal serum biochemical indicators in Down syndrome. Prenat Diagn 10: 245-251, 1990.
Newby D, Aitken DA, Crossley JA et al. Biochemical markers of trisomy 21 and the pathophysiology of Down’s syndrome pregnancies. Prenat Diagn 17: 941-951, 1997.
Ind TE, Iles RK, Cuckle HS et al. Second-trimester maternal serum placental alkaline phosphatase concentrations in Down syndrome. J Obstet Gynecol 14: 305-308, 1994.
Peleg L, Ries L, Getslev V et al. Heat stable and urea resistant alkaline phosphatase in maternal neutrophils from normal and Down syndrome pregnancies. Prenat Diagn 19: 224-228, 1999.
Denier CC, Brisson-Lougarre AA, Biasini GG et al. Kinetic comparison of tissue non-specific and placental human alkaline phosphatases expressed in baculovirus infected cells: application to screening for Down's syndrome. BMC Biochem 3: 2-9, 2002.
Makiya R, Stigbrand T. Placental alkaline phosphatase has a building site for the human immunglobulin G Fc portion. Eur J Biochem 205: 341-345, 1992.